Navigation Links
ZEISS Ends Successful Fiscal Year 2012/13
Date:12/12/2013

STUTTGART, Germany, December 12, 2013 /PRNewswire/ --

Revenue Reaches New Record High

ZEISS has brought fiscal year 2012/13 to a successful conclusion (reporting date: 30 September 2013) with a new record high in revenue. The company generated revenue totaling EUR 4.190 billion (prior year: EUR 4.163 billion) and earnings (EBIT) of EUR 335 million (prior year: EUR 420 million). The Industrial Metrology and Medical Technology business groups recorded particularly strong growth. "In fiscal year 2012/13 we reached and partly exceeded our targets. ZEISS put in a good performance despite the challenging business environment and the weakness of the economy at the beginning of the year," said Dr. Michael Kaschke, President and CEO of Carl Zeiss AG. "We made no compromises in our multi-year investment program - the biggest ever in the company's history - but continued to implement it consistently and systematically."

The number of employees increased to 24,623 worldwide. The company increased its expenditure on research and development activities by five percent to EUR 411 million. Investments in property, plant and equipment totaled EUR 245 million.

More information at http://www.zeiss.com/press

ZEISS is an international leader in the fields of optics and optoelectronics. The more than 24,000 employees of ZEISS generated revenue of about 4.2 billion euros in fiscal year 2012/13. Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. ZEISS has been contributing to technological progress for more than 160 years. ZEISS develops and produces solutions for the semiconductor, automotive and mechanical engineering industries, biomedical research and medical technology, as well as eyeglass lenses, camera and cine lenses, binoculars and planetariums. ZEISS is present in over 40 countries around the globe with more than 40 production facilities, around 50 sales and service locations and over 20 research and development sites. Carl Zeiss AG is fully owned by the Carl Zeiss Stiftung (Carl Zeiss Foundation).

Press contact
ZEISS Group
Jörg Nitschke, Pressesprecher
Phone +49-07364-20-3242
Email: joerg.nitschke@zeiss.com


'/>"/>
SOURCE Carl Zeiss AG
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ophthalmic Instrumentation - Global Strategic Business Report - 2012 Featuring Abbott, Bausch & Lomb, Carl Zeiss and Others
2. Carl Zeiss continúa en ruta hacia el crecimiento futuro e inversión
3. Carl Zeiss Continues on Track to Further Growth and Investment
4. Sangamo BioSciences Presents Clinical Data From Key SB-728-T HIV Studies: Proof Of Concept For Ongoing Sustained Functional Control Of HIV Viral Load; Cytoxan Preconditioning Successfully Enhances Engraftment
5. Orexigen Announces Successful Interim Analysis of Contrave Light Study
6. QRxPharma Announces Successful Completion Of A$7.5 Million Placement
7. WuXi AppTec Successfully Completes Its First 2000L Disposable Bioreactor Run Using an NS0 Cell Line, Marking an Industry Milestone
8. Palatin Technologies Reports Successful Completion Of Device Bioequivalence Trial
9. Biocartis Presents the Successful use of Idylla[TM] for the Detection of the BRAF Mutation Status in Tumour Samples at the International AACR Congress (American Association for Cancer Research) in Boston
10. Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer
11. Overcoming Regional Marketplace Complexities to Successfully Launch a Global Brand Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017 /PRNewswire/ ... USD 330.6 million by 2021 from USD 275.9 ... Read the full report: http://www.reportlinker.com/p04718602-summary/view-report.html ... industries, increasing spending on pharmaceutical R&D, and growth ... factors driving the market growth for particle counters. ...
(Date:2/24/2017)... Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology ... it has acquired exclusive worldwide rights to develop, ... HDAC inhibitor targeting hematological and solid tumors. ... 1 and 2 clinical trials of Abexinostat in ... have already been completed, demonstrating that Abexinostat is ...
(Date:2/23/2017)... BOSTON , Feb. 23, 2017 ... devices and services since 1997, is changing the ... modern technology providing patients with pro-active, custom-made solutions. ... desire for instant and affordable healthcare without walls, ... of high-level devices developed with healthcare professionals that ...
Breaking Medicine Technology:
(Date:2/23/2017)... TX (PRWEB) , ... February 23, 2017 , ... ... announced an official 2017 partnership with The Jensie Gran Fondo of Marin. For ... and UVB rays with Thinksport’s broad-spectrum, mineral-based sunscreen. , “We are thrilled to ...
(Date:2/23/2017)... ... 2017 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Beach to host its Swirl: Miami Wine Tasting Event on March 28, 2017. ...
(Date:2/23/2017)... Los Angeles, CA (PRWEB) , ... February 23, 2017 , ... ... the first two episodes of WE TV’s “Mama June: From Not to Hot,” which ... of TV notable, “Mama” June Shannon, known to millions from the 2012 reality television ...
(Date:2/23/2017)... ... 23, 2017 , ... EBSCO Information Services (EBSCO) ... for Health and Care Excellence (NICE) framework. The agreement allows purchasers from ... to search, order and purchase medical and healthcare-related content through GOBI ®, ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... new, interactive publication where generations converge and explore the world from different perspectives. ... Dialog Magazine enables readers to gain understanding, increase empathy, and find greater happiness. ...
Breaking Medicine News(10 mins):